Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock (VASST)
Source: View publication →
The VASST trial demonstrated that in patients with septic shock requiring norepinephrine, the addition of low-dose vasopressin (0.01 to 0.03 U/min) did not significantly reduce 28-day mortality compared to norepinephrine infusion alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The VASST trial established that low-dose vasopressin is a safe, effective vasopressor-sparing agent in septic shock, and it remains a standard adjunct in current guidelines for patients refractory to norepinephrine. While it did not prove a universal mortality benefit, it provided the foundation for its widespread use in clinical practice to support blood pressure and reduce catecholamine requirements.
Historical Context
Prior to VASST, vasopressin was hypothesized to be beneficial because septic shock is characterized by a relative deficiency of endogenous vasopressin, and catecholamine-refractory shock was a major clinical challenge. The trial aimed to address the uncertainty regarding the mortality benefit of adding vasopressin to conventional catecholamine therapy in the management of septic shock.
Guided Discussion
High-yield insights from every perspective
The VASST trial investigated the use of vasopressin in septic shock. From a pathophysiological perspective, why is there a 'relative vasopressin deficiency' in late-stage septic shock, and how does the mechanism of V1a receptor stimulation differ from alpha-1 adrenergic stimulation in achieving vasoconstriction?
Key Response
In early sepsis, vasopressin levels are high to maintain blood pressure, but in late/prolonged sepsis, stores in the posterior pituitary become exhausted. While alpha-1 receptors (norepinephrine) act via the Gq-PLC-IP3 pathway to increase intracellular calcium, V1a receptors also use the Gq pathway but uniquely inhibit ATP-sensitive potassium channels and modulate nitric oxide pathways, making vasopressin effective even in the acidic environments often found in refractory shock.
The primary outcome of the VASST trial was 28-day mortality, which showed no significant difference between the vasopressin and norepinephrine groups. Given this result, what is the clinical justification for the common practice of adding low-dose vasopressin (0.01–0.03 U/min) to a patient already on norepinephrine?
Key Response
The primary justification is the 'norepinephrine-sparing' effect. VASST demonstrated that adding vasopressin significantly reduced the required dose of norepinephrine to maintain target MAP. This potentially limits catecholamine-induced toxicities such as tachyarrhythmias, myocardial ischemia, and immunomodulation, even if a broad mortality benefit was not proven for the entire cohort.
A subgroup analysis in VASST suggested a potential mortality benefit of vasopressin in patients with 'less severe' septic shock (defined as norepinephrine requirement <15 mcg/min). How do you reconcile this with the traditional practice of using vasopressin only as a 'rescue' therapy in refractory shock?
Key Response
The subgroup analysis (26.5% vs 35.7% mortality) suggests that earlier initiation—before profound multi-organ failure and irreversible vasoplegia set in—might be more effective. However, because this was a post-hoc subgroup analysis, it remains hypothesis-generating. It challenges the 'rescue only' mindset, suggesting vasopressin might be better utilized as a second-line agent when norepinephrine doses are moderate rather than waiting for extreme doses.
How did the VASST trial's findings regarding renal replacement therapy (RRT) requirements and serum creatinine levels influence your teaching on the 'renal-protective' effects of vasopressin compared to norepinephrine?
Key Response
VASST did not show a significant difference in the requirement for RRT or the rate of renal recovery in the overall population. However, in the 'less severe' shock subgroup, there was a trend toward lower RRT rates. This teaches us that while vasopressin preferentially constricts the efferent arteriole (potentially increasing GFR), it should not be prescribed specifically for 'renal protection' outside of its role as a vasopressor.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The VASST trial utilized a fixed-dose protocol for vasopressin (0.03 U/min) rather than a titration-to-effect strategy. Discuss the implications of this design choice on the trial's internal validity and its ability to detect a true therapeutic window, particularly considering the pharmacokinetics of exogenous vasopressin in critically ill patients.
Key Response
Fixed dosing ensures protocol adherence and minimizes confounding by clinician behavior, but it ignores inter-individual variability in vasopressin clearance and receptor sensitivity. In septic shock, V1 receptor downregulation varies; a fixed dose might be 'supraphysiologic' for some and 'subtherapeutic' for others, potentially masking a benefit that a titration-to-MAP strategy might have uncovered, albeit at the cost of higher risk for ischemic complications.
As a reviewer, if the VASST authors had presented their 'less severe shock' subgroup findings as a primary conclusion rather than a hypothesis-generating secondary analysis, what specific statistical and methodological concerns would you raise to protect the journal's integrity?
Key Response
An editor would flag the risk of Type I error (false positive) due to multiple comparisons. Without pre-stratification during randomization and a formal interaction test showing a significant treatment-by-subgroup effect, the findings are susceptible to 'p-hacking' or 'data dredging.' The editor would insist the results be framed strictly as exploratory to avoid misleading clinicians into over-interpreting a secondary finding in an otherwise neutral trial.
Current Surviving Sepsis Campaign guidelines suggest adding vasopressin to norepinephrine with the intent of raising MAP to target or decreasing norepinephrine dosage. How does the VASST trial serve as the evidence base for this 'Weak Recommendation, Moderate Quality of Evidence,' and why has it not led to a 'Strong' recommendation for vasopressin as a first-line agent?
Key Response
VASST provides the highest level of evidence that vasopressin is a safe adjunct but failed to meet its primary mortality endpoint for the general population. Because it is not superior to norepinephrine (as shown by the 35.4% vs 39.3% mortality difference which failed to reach significance), it cannot be a first-line 'Strong' recommendation. The recommendation remains 'Weak' because the benefits are primarily physiological (sparing catecholamines) rather than a robust, reproducible survival advantage across all sepsis phenotypes.
Clinical Landscape
Noteworthy Related Trials
SOAP-II Trial
Tested
Dopamine
Population
Patients with shock
Comparator
Norepinephrine
Endpoint
28-day mortality
VANISH Trial
Tested
Vasopressin
Population
Patients with septic shock
Comparator
Norepinephrine
Endpoint
Kidney failure-free days at day 28
CAT Trial
Tested
Early vasopressin
Population
Patients with septic shock
Comparator
Norepinephrine
Endpoint
Mean arterial pressure achievement
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis